15.07.2010 • News

Süd-Chemie Invests €60 Million in Lithium Iron Phosphate Production

Süd-Chemie AG is investing approximately €60 million in the production of lithium iron phosphate (LFP), a high performance energy storage material used in batteries for electric vehicle drives and other applications. On the new site of its wholly-owned Canadian subsidiary, Phostech Lithium. In Candiac, Quebec, the German group is constructing the first industrial production plant for LFP using a new, proprietary production process based-on wet chemistry.

Commercial production for series delivery will start in 2012 to reach a rate of 2,500 tons per year. Such volume, will allow the production of approximately 50,000 all-electric automobiles or, alternatively, up to 500,000 vehicles with hybrid drive per year. As a result of the high demand, Süd-Chemie is considerably expanding its production capacity for LFP based on its new wet chemistry production process a technology by which Süd-Chemie can already currently manufacture up to 300 tons of LFP per year at its site in Moosburg, Germany.

Besides electric vehicle drives, the LFP has great potential in high-performance storage batteries, e.g. for stabilizing peak supply or for storing photovoltaic electricity. In addition, LFP manufactured by Süd-Chemie is already successfully used in power tools, starter batteries for passenger vehicles, and electric scooters in Europa, Asia, and North America.

Company

Süd-Chemie

Lenbachplatz 6
80333 München
Germany

Company contact







Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read